Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles

Tumor Biology

Volumn 37, Issue 6, 2016, Pages 8403-8412

  Jadidi Niaragh, Farhad ^a,b,c   Atyabi, Fatemeh ^d   Rastegari, Ali ^d   Mollarazi, Esmail ^e   Kiani, Melika ^d   Razavi, Alireza ^a   Yousefi, Mehdi ^b,c   Kheshtchin, Nasim ^f   Hassannia, Hadi ^a   Hadjati, Jamshid ^f   Shokri, Fazel ^a,g  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e Food and Drug Control Laboratories Food and Drug Laboratory Research Centre MOHME   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Cancer; CD73; Nanoparticle; siRNA; Treatment

Indexed keywords

5' NUCLEOTIDASE; CHITOSAN; GREEN FLUORESCENT PROTEIN; HEPARIN; LACTIC ACID; NANOPARTICLE; SMALL INTERFERING RNA; TRIPOLYPHOSPHATE;

4T1 CELL LINE; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DEGRADATION; DEPOLYMERIZATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG RELEASE; FLOW CYTOMETRY; GELATION; GENE EXPRESSION; GENETIC TRANSFECTION; IN VITRO STUDY; INFRARED SPECTROSCOPY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; BREAST NEOPLASMS; CELL SURVIVAL; FEMALE; GENETICS; METABOLISM; MOUSE; TUMOR CELL LINE;

5'-NUCLEOTIDASE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHITOSAN; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; LACTIC ACID; MICE; NANOPARTICLES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84953270491     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4732-0     Document Type: Article

References (43)

1. Yousefi M, Movassaghpour AA, Shamsasenjan K, Ghalamfarsa G, Sadreddini S, Jadidi-Niaragh F, et al. The skewed balance between tregs and th17 in chronic lymphocytic leukemia. Future Oncol. 2015;11:1567–82.
2. Jadidi-Niaragh F, Ghalamfarsa G, Yousefi M, Tabrizi MH, Shokri F. Regulatory t cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions. Tumor Biol. 2013;34:2031–9.
3. Jadidi-Niaragh F, Yousefi M, Memarian A, Hojjat-Farsangi M, Khoshnoodi J, Razavi SM, et al. Increased frequency of cd8+ and cd4+ regulatory t cells in chronic lymphocytic leukemia: association with disease progression. Cancer Investig. 2013;31:121–31.
4. Motallebnezhad M, Jadidi-Niaragh F, Qamsari ES, Bagheri S, Gharibi T, Yousefi M. The immunobiology of myeloid-derived suppressor cells in cancer. Tumor Biol. 2015;1–20.
5. Yazdani Y, Mohammadnia-Afrouzi M, Yousefi M, Anvari E, Ghalamfarsa G, Hasannia H, et al. Myeloid-derived suppressor cells in b cell malignancies. Tumor Biol. 2015;1–15.
6. Raggi C, Mousa H, Correnti M, Sica A, Invernizzi P. Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene. 2015.
7. Ghalamfarsa G, Hadinia A, Yousefi M, Jadidi-Niaragh F. The role of natural killer t cells in b cell malignancies. Tumor Biol. 2013;34:1349–60.
8. Jadidi-Niaragh F, Jeddi-Tehrani M, Ansaripour B, Razavi SM, Sharifian RA, Shokri F. Reduced frequency of nkt-like cells in patients with progressive chronic lymphocytic leukemia. Med Oncol. 2012;29:3561–9.
9. Ding T, Yan F, Cao S, Ren X. Regulatory b cell: new member of immunosuppressive cell club. Hum Immunol. 2015.
10. Kazemi T, Younesi V, Jadidi-Niaragh F, Yousefi M. Immunotherapeutic approaches for cancer therapy: an updated review. Artificial cells, nanomedicine, and biotechnology. 2015;1–11.
11. Haji-Fatahaliha M, Hosseini M, Akbarian A, Sadreddini S, Jadidi-Niaragh F, Yousefi M. Car-modified t-cell therapy for cancer: an updated review. Artif Cells Nanomedicine Biotechnol. 2015;1–11.
12. Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014;4:879–88.
13. Gao Z-w, Dong K, Zhang H-z: The roles of cd73 in cancer. BioMed Res Int 2014;2014
14. Zhang B. Cd73: a novel target for cancer immunotherapy. Cancer Res. 2010;70:6407–11.
15. Hosseini M, Haji-Fatahaliha M, Jadidi-Niaragh F, Majidi J, Yousefi M. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif Cells Nanomedicine Biotechnol. 2015;1–11.
16. Tahamtan A, Tabarraei A, Moradi A, Dinarvand M, Kelishadi M, Ghaemi A, et al. Chitosan nanoparticles as a potential nonviral gene delivery for hpv-16 e7 into mammalian cells. Artif Cells Nanomedicine Biotechnol. 2014;1–7.
17. Mollarazi E, Jalilian AR, Johari‐daha F, Atyabi F. Development of 153sm-folate-polyethyleneimine-conjugated chitosan nanoparticles for targeted therapy. J Label Compd Radiopharm. 2015;58:327–35.
18. Talaei F, Azizi E, Dinarvand R, Atyabi F. Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against egfr in t47d breast cancer cells. Int J Nanomedicine. 2011;6:1963.
19. Cheung RCF, Ng TB, Wong JH, Chan WY. Chitosan: an update on potential biomedical and pharmaceutical applications. Marine drugs. 2015;13:5156–86.
20. Molinaro R, Wolfram J, Federico C, Cilurzo F, Di Marzio L, Ventura CA, et al. Polyethylenimine and chitosan carriers for the delivery of rna interference effectors. Expert Opin Drug Del. 2013;10:1653–68.
21. Shikata F, Tokumitsu H, Ichikawa H, Fukumori Y. In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer. Eur J Pharm Biopharm. 2002;53:57–63.
22. Thanou M, Florea B, Geldof M, Junginger H, Borchard G. Quaternized chitosan oligomers as novel gene delivery vectors in epithelial cell lines. Biomaterials. 2002;23:153–9.
23. Corsi K, Chellat F, Yahia LH, Fernandes JC. Mesenchymal stem cells, mg63 and hek293 transfection using chitosan-DNA nanoparticles. Biomaterials. 2003;24:1255–64.
24. Wan L, Hu F, Yuan H. study of the uptake of chitosan oligosaccharide nanoparticles by a549 cells]. Yao xue xue bao. Acta Pharm Sin. 2004;39:227–31.
25. Dastan T, Turan K. In vitro characterization and delivery of chitosan-DNA microparticles into mammalian cells. J Pharm Pharm Sci. 2004;7:205–14.
26. Zhao X, Yu S-B, Wu F-L, Mao Z-B, Yu C-L. Transfection of primary chondrocytes using chitosan-pegfp nanoparticles. J Control Release. 2006;112:223–8.
27. Weecharangsan W, Opanasopit P, Ngawhirunpat T, Apirakaramwong A, Rojanarata T, Ruktanonchai U, et al. Evaluation of chitosan salts as non-viral gene vectors in cho-k1 cells. Int J Pharm. 2008;348:161–8.
28. Weecharangsan W, Opanasopit P, Ngawhirunpat T, Rojanarata T, Apirakaramwong A. Chitosan lactate as a nonviral gene delivery vector in cos-1 cells. AAPS PharmSciTech. 2006;7:E74–9.
29. Moghaddam FA, Atyabi F, Dinarvand R. Preparation and in vitro evaluation of mucoadhesion and permeation enhancement of thiolated chitosan-phema core-shell nanoparticles. Nanomedicine: Nanotechnol, Biol Med. 2009;5:208–15.
30. Akhlaghi SP, Saremi S, Ostad SN, Dinarvand R, Atyabi F. Discriminated effects of thiolated chitosan-coated pmma paclitaxel-loaded nanoparticles on different normal and cancer cell lines. Nanomedicine: Nanotechnol, Biol Med. 2010;6:689–97.
31. Takedachi M, Qu D, Ebisuno Y, Oohara H, Joachims ML, McGee ST, et al. Cd73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J Immunol. 2008;180:6288–96.
32. Yegutkin GG, Marttila‐Ichihara F, Karikoski M, Niemelä J, Laurila JP, Elima K, et al. Altered purinergic signaling in cd73‐deficient mice inhibits tumor progression. Eur J Immunol. 2011;41:1231–41.
33. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, et al. Cd73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest. 2011;121:2371.
34. Zhi X, Chen S, Zhou P, Shao Z, Wang L, Ou Z, et al. Rna interference of ecto-5′-nucleotidase (cd73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis. 2007;24:439–48.
35. Stagg J, Beavis PA, Divisekera U, Liu MC, Möller A, Darcy PK, et al. Cd73-deficient mice are resistant to carcinogenesis. Cancer Res. 2012;72:2190–6.
36. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, et al. Anti-cd73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci. 2010;107:1547–52.
37. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, et al. Cd73 on tumor cells impairs antitumor t-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70:2245–55.
38. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, et al. Cd73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011;71:2892–900.
39. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, et al. Crucial role for ecto-5′-nucleotidase (cd73) in vascular leakage during hypoxia. J Exp Med. 2004;200:1395–405.
40. Wang L, Tang S, Wang Y, Xu S, Yu J, Zhi X, et al. Ecto-5′-nucleotidase (cd73) promotes tumor angiogenesis. Clin Exp Metastasis. 2013;30:671–80.
41. Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maiolino P, et al. Inhibition of cd73 improves b cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol. 2012;189:2226–33.
42. Zhi X, Wang Y, Zhou X, Yu J, Jian R, Tang S, et al. Rnai-mediated cd73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci. 2010;101:2561–9.
43. Kiang T, Wen J, Lim HW, Leong KW. The effect of the degree of chitosan deacetylation on the efficiency of gene transfection. Biomaterials. 2004;25:5293–301.